Evofem expects merger approval at Sept. 26 stockholder meeting

Evofem Biosciences Inc. (OTC: EVFM) stated it anticipates approval of its merger with Aditxt Inc. (NASDAQ: ADTX) at a special stockholder meeting scheduled for September 26, 2025, according to a press release.

CEO Saundra Pelletier said the company has support agreements with holders of Series E-1 and G-1 shares sufficient to approve the merger, along with backing from other key investors. The merger requires approval from at least a majority of the combined voting power of common stock, Series E-1 and G-1 shares.

Under the merger agreement dated July 12, 2024, Adifem Inc., a wholly-owned subsidiary of Aditxt, will merge with Evofem. Evofem will survive as a wholly-owned subsidiary of Aditxt and form the core of a women's health program within Aditxt's platform.

As of August 26, 2025, Evofem had 118,656,354 shares of common stock outstanding. Holders of Series E-1 and G-1 shares control 13.87% and 39.84% respectively of Evofem's combined voting power, totaling 53.71%.

The company filed definitive proxy materials with the Securities and Exchange Commission on September 8, 2025. Closing conditions include majority approval from stockholders, individual majority votes from Series E-1 and G-1 holders, Aditxt raising sufficient capital for closing obligations, and other customary conditions.

Evofem commercializes two FDA-approved products: PHEXXI, a hormone-free prescription contraceptive vaginal gel, and SOLOSEC, an oral antibiotic for treating bacterial vaginosis and trichomoniasis.

You May Also Be Interested In

• Rapid Line sees stock surge with no known corporate cause
• Aurora Cannabis acquires two UK pharma firms for £2.1 million
• Datavault AI agrees to acquire Wyoming bank BankWyse